FIVE YEAR PROGNOSIS IN PATIENTS WITH CORONARY HEART DISEASE AND COMORBIDITIES: DATA FROM MULTICENTER STUDY IN INGUSHETIA REPUBLIC

Aim. Analysis of the primary endpoints occurence in male and female cohort of coronary heart disease (CHD) patients comorbid with other somatic pathology, during 5 years.

Material and methods. To the study, 320 patients included (143 males, 177 females, age 46-72 y. o.) with CHD stable angina I-III functional class, and underwent investigations in the year 2012 in three medical centers in the Republic of Ingushetia. In 2017 patients were invited for second investigation or were contacted by phone. As the primary endpoints the following accounted: revascularization surgery (CBG), endovascular surgery in coronary, carotid, peripheral arteries, diagnosed myocardial infarction, ischemic stroke, diabetes and its complications, fatal outcome from cardiovascular diseases (CVD) and death from other causes.

Results. The number of CHD patients with comorbidities was 196, and with no comorbidities — 124. During the follow-up, stroke developed in 17 (5 males, 11 females) patients, myocardial infarction in 37 (20 males, 17 females), diabetes in 38 (15 males, 23 females), fatal CVD outcome in 11 (8 males, 3 females; of those in 5 — acute coronary syndrome, 4 — stroke, 3 — chronic heart failure),
and death from other causes in 8 (5 males, 3 females). We also analyzed the development of composite endpoints in CHD patients depending on the presence and absence of comorbidities. Stroke was registered in 13 comorbid patients vs 3 in CHD with no other diseases. Myocardial infarction found in 33 patients with CHD and three comorbidities vs 4 cases in CHD with no comorbidities. Diabetes was found in 32 vs 6 patients, respectively; CVD death in 10 vs 1, resp.; all-cause death in 5 vs 3, resp.

Conclusion. Comorbid CHD with 2 and more somatic diseases, during the 5-year period of follow-up, does increase the risk of complications and death from CVD.

1. Atlas Writing Group Adam Timmis Nick Townsend Chris Gale Rick Grobbee Nikos Maniadakis Marcus Flather Elizabeth Wilkins Lucy Wright Rimke Vos et al. European Society of Cardiology: Cardiovascular Disease Statistics 2017. European Heart Journal, ehx628. DOI: 10.1093/eurheartj/ehx628.

2. World Health Organisation. Global Health Observatory (GHO) data. http://www.who.int/gho/ncd/risk_factors/cholesterol_prevalence/en/ (17 April 2017).

3. Boytsov SA, Lukyanov MM, Yakushin SS, et al. Register of cardiovascular diseases (REKVAZA): diagnostics, combined cardiovascular pathology, concomitant diseases and treatment in conditions of real out-patient polyclinic practice. Cardiovascular therapy and prevention 2014; 13 (6): 44-50. (In Russ.) Бойцов С. А., Лукьянов М. М., Якушин C. С., и др. Регистр кардиоваскулярных заболеваний (РЕКВАЗА): диагностика, сочетанная сердечно-сосудистая патология, сопутствующие заболевания и лечение в условиях реальной амбулаторно-поликлинической практики. Кардиоваскулярная терапия и профилактика 2014; 13 (6): 44-50. DOI:10.15829/1728-8800-2014-6-44-50.

4. Rumyantseva SA, Oganov RG, Silina EV Modern concepts of treatment of patients with vascular comorbidity. Cardiovascular therapy and prevention. 2012; 11 (6): 50-5. (In Russ.) Румянцева С. А., Оганов Р. Г., Силина Е. В. Современные концепции лечения пациентов с сосудистой коморбидностью. Кардиоваскулярная терапия и профилактика. 2012; 11 (6): 50-5.

5. Arnett DK, Goodman RA, Halperin JL, et al. AHA/ACC/HHS strategies to enhance application of clinical practice guidelines in patients with cardiovascular disease and comorbid conditions: from the American Heart Association, American College of Cardiology, and U. S. Department of Health and Human Services. J Am Coll Cardiol. 2014; 64 (17): 1851-56.

6. Tolpygina SN, Martsevich SYu. The effect of concomitant diseases on the long-term prognosis of patients with chronic coronary artery disease according to the data of the CHD FORECAST registry. Rational pharmacotherapy in cardiology. 2015; 11 (6): 571-6. (In Russ.) Толпыгина С. Н., Марцевич С. Ю. Влияние сопутствующих заболеваний на отдаленный прогноз пациентов с хронической ИБС по данным регистра ПРОГНОЗ ИБС. Рациональная фармакотерапия в кардиологии. 2015; 11 (6): 571-76.

7. Mamedov MN, Didigova RT, Ugurchieva ZO, Inarokova AM. Priorities of secondary prevention of coronary heart disease in a depressed region: preliminary results of the North Caucasian project. Cardiology 2011; 12: 4-10. (In Russ.) Мамедов М. Н., Дидигова Р. Т., Угурчиева З. О., Инарокова А. М. Приоритеты вторичной профилактики ишемической болезни сердца в условиях депрессивного региона: предварительные результаты Северо-Кавказского проекта. Кардиология. 2011; 12: 4-10.

8. Badeynikova KK, Mazaev AP, Toguzova ZA, et al. Identification of early markers of atherosclerosis in men with different levels of risk of developing cardiovascular complications. Cardiology 2014; 6: 35-9. (In Russ.) Бадейникова К. К., Мазаев А. П., Тогузова З. А., и др. Определение ранних маркеров атеросклероза у мужчин с различным уровнем риска развития сердечно-сосудистых осложнений. Кардиология. 2014; 6: 35-9.

9. Metelskaya VA, Gavrilova NE, Yarovaya EA, Boytsov SA. An integrative boimarker: opportunities for non-invasive diagnostics of coronary atherosclerosis s. Russian Cardiology Journal. 2017; 6: 132-8. (In Russ.) Метельская В. А., Гаврилова Н. Е., Яровая Е. А., Бойцов С. А. Интегрированный биомаркер: возможности неинвазивной диагностики коронарного атеросклероза. Российский кардиологический журнал. 2017; 6: 132-8. DOI:10.15829/1560-4071-2017-6-132-138.